AstraZeneca, Stockholders Far Apart In Merger Damages Tally
Syntimmune Inc. stockholders and Alexion Pharmaceuticals have landed tens of millions of dollars apart in new tallies of interest owed after a Court of Chancery ruling in June that Alexion failed...To view the full article, register now.
Already a subscriber? Click here to view full article